Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma

Katia Grillone, Serena Ascrizzi, Paolo Cremaschi, Jussara Amato, Nicoletta Polerà, Ottavio Croci, Roberta Rocca, Caterina Riillo, Francesco Conforti, Raffaele Graziano, Diego Brancaccio, Daniele Caracciolo, Stefano Alcaro, Bruno Pagano, Antonio Randazzo, Pierosandro Tagliaferri, Francesco Iorio, Pierfrancesco Tassone

Blood (2024) 144 (16): 1705–1721.

https://doi.org/10.1182/blood.2023021991

Published: 2024

Includes: Supplemental data

Journal Articles

A Novel Bispecific T Cell Engager (UMG2-BTCE) Targeting CD1a-CD3ε Is Effective Against Cortical-Derived Acute Lymphoblastic Leukemia

Caterina Riillo, Daniele Caracciolo, Katia Grillone, Nicoletta Polerà, Giada Juli, Francesca Scionti, Serena Ascrizzi, Franca Maria Tuccillo, Patrizia Bonelli, Mariamena Arbitrio, Maria Teresa Di Martino, Pierosandro Tagliaferri, Pierfrancesco Tassone

Blood (2021) 138 (Supplement 1): 2259.

https://doi.org/10.1182/blood-2021-153043

Published: 2021

Journal Articles

Global Rnaseq/Proteomic-Phoshoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM

Marco Rossi, MD, Emanuela Altomare, PhD, Cirino Botta, MD, Maria Eugenia Gallo Cantafio, Marco Gaspari, Domenico Taverna, Sarvide Sarai, Daniele Caracciolo, MD, Paola Critelli, MD, Francesco Conforti, Maria Teresa Di Martino, PhD, Bruno Paiva, PhD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2019) 134 (Supplement_1): 505.

https://doi.org/10.1182/blood-2019-122429

Published: 2019

Journal Articles

PARP1-Mediated Alt-NHEJ Repair Is a Therapeutic Target in Multiple Myeloma

Daniele Caracciolo, MD, Giada Juli, PhD, Francesca Scionti, PhD, Gaetanina Golino, PhD, Mariamena Arbitrio, MD, Emanuela Altomare, PhD, Katia Todoerti, PhD, Katia Grillone, PhD, Maria Teresa Di Martino, PhD, Marco Rossi, MD, Antonino Neri, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2019) 134 (Supplement_1): 3107.

https://doi.org/10.1182/blood-2019-128245

Published: 2019

Journal Articles

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92

Blood (2018) 132 (10): 1050–1063.

https://doi.org/10.1182/blood-2018-03-836601

Published: 2018

Includes: Supplemental data

Journal Articles

Th17 Cells Targeting By MiR-21 Inhibitor Impairs Multiple Myeloma Related Bone Disease

Marco Rossi, Emanuela Altomare, Nicola Amodio, PhD, Maria Teresa Di Martino, Marco Gaspari, Domenico Taverna, Domenica Scumaci, Francesco Conforti, Daniele Caracciolo, Cirino Botta, Cinzia Federico, Annamaria Gullà, Eugenio Morelli, Francesca Scionti, Mariamena Arbitrio, MD, Paola Critelli, Antonino Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone, MD

Blood (2017) 130 (Supplement 1): 4380.

https://doi.org/10.1182/blood.V130.Suppl_1.4380.4380

Published: 2017

Journal Articles

Life Expectancy in Follicular Lymphoma Is Mainly Determined By Response to First LINE Treatment: A LONG-TERM Survey on 597 Patients

Corrado Tarella, MD, Angela Gueli, Federica Delaini, Anna Maria Barbui, MD, Riccardo Bruna, Daniele Caracciolo, Daniela Gottardi, Giuseppe Gritti, MD, Roberto Passera, PharmD, PhD, Safaa Ramadan, PhD MD, Andrea Rossi, MD, Alessandro Rambaldi, MD

Blood (2015) 126 (23): 3989.

https://doi.org/10.1182/blood.V126.23.3989.3989

Published: 2015

Journal Articles

Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role of the Classical and Alternative Pathways in Genomic Instability

Teresa Calimeri, MD PhD, Daniele Caracciolo, MD, Nicola Amodio, PhD, Mehmet Kemal Samur, PhD, Marzia Leotta, MD, Mariateresa Fulciniti, PhD, Marco Rossi, MD, Stephane Minvielle, Herve Avet-Loiseau, Pierosandro Tagliaferri, MD, Masood Shammas, PhD, Kenneth C. Anderson, Pierfrancesco Tassone, MD, Nikhil C. Munshi, MD

Blood (2014) 124 (21): 3417.

https://doi.org/10.1182/blood.V124.21.3417.3417

Published: 2014

Journal Articles

Relapsed Or Refractory Aggressive Non Hodgkin B-Cell Lymphomas Treated With Lenalidomide With/Without Rituximab Or Steroids: A Single Center Restrospective Study

Alessia Castellino, Annalisa Chiappella, Paola Ghione, Manuela Ceccarelli, Giulia Benevolo, MD, Barbara Botto, Daniele Caracciolo, Chiara Ciochetto, Maura Nicolosi, Lorella Orsucci, Clara Pecoraro, Patrizia Pregno, Paola Riccomagno, Manuela Zanni, Marco Ladetto, Umberto Vitolo, MD

Blood (2013) 122 (21): 5119.

https://doi.org/10.1182/blood.V122.21.5119.5119

Published: 2013

Journal Articles

In Vitro and Vivo Activity Against Multiple Myeloma Cells Of a Novel Locked Nucleic Acid (LNA)-Mir-221 Inhibitor

Maria Teresa Di Martino, PhD, Annamaria Gullà, MD, Maria Eugenia Gallo Cantafio, Emanuela Altomare, PhD, Nicola Amodio, PhD, Emanuela Leone, PhD, Santo Giovanni Lio, Eugenio Morelli, MD, Daniele Caracciolo, MD, Cirino Botta, MD, Antonino Neri, MD, Niels M Frandsen, PhD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2013) 122 (21): 3166.

https://doi.org/10.1182/blood.V122.21.3166.3166

Published: 2013

Journal Articles

The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab

Alessandro Rambaldi, MD, Cristina Boschini, Federica Delaini, BiolSC, Elena Oldani, BiolSC, Andrea Rossi, MD, Anna Maria Barbui, MD, Giuseppe Gritti, MD, Daniele Caracciolo, MD, Marco Ladetto, MD, Angela Gueli, MD, Alberto De Crescenzo, MD, Roberto Passera, PhD, Liliana Devizzi, MD, Alessandro M. Gianni, MD, Corrado Tarella, MD

Blood (2012) 120 (21): 1553.

https://doi.org/10.1182/blood.V120.21.1553.1553

Published: 2012

Journal Articles

Primary Refractory Disease in Non-Hodgkin's Lymphoma: A Retrospective Study On 3,952 Newly Diagnosed Patients Undergoing First-Line Chemotherapy

Corrado Tarella, MD, Angela Gueli, MD, Federica Delaini, BiolSC, Andrea Rossi, MD, Anna Maria Barbui, MD, Giuseppe Gritti, MD, Daniele Caracciolo, Huijing Hu, MD, Daniela Gottardi, MD, Roberto Passera, PharmD PhD, Alessandro Rambaldi, MD

Blood (2012) 120 (21): 305.

https://doi.org/10.1182/blood.V120.21.305.305

Published: 2012

Journal Articles

Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial

Andrés J. M. Ferreri, Silvia Govi, Markus Raderer, Antonino Mulè, Alessandro Andriani, Daniele Caracciolo, Liliana Devizzi, Fiorella Ilariucci, Stefano Luminari, Edi Viale, Leonhard Müllauer, Stefania Dell'Oro, Paolo Giorgio Arcidiacono, Maurilio Ponzoni, Caterina Patti

Blood (2012) 120 (18): 3858–3860.

https://doi.org/10.1182/blood-2012-06-438424

Published: 2012

Journal Articles

Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results,

Marco Ruella, MD, Andrea Filippi, MD, Anna DI Russo, MD, Daniele Caracciolo, MD, Paola Matteucci, MD, Michele Magni, MD, Massimo Di Nicola, MD, Umberto Ricardi, MD, Vittorio Montefusco, MD, Guido Parvis, MD, Corrado Tarella, MD, Alessandro M. Gianni, MD, Liliana Devizzi, MD

Blood (2011) 118 (21): 3699.

https://doi.org/10.1182/blood.V118.21.3699.3699

Published: 2011

Journal Articles

Final Results of a Multicenter Phase II Trial Assessing the Activity and Efficacy of Helicobacter Pylori -Eradicating Antibiotic Therapy As Exclusive Treatment for Patients with Stage I-II1 Diffuse Large B-Cell Lymphoma of the Stomach (the HGL-1 Trial)

Silvia Govi, MD, Caterina Patti, MD, Markus Raderer, MD, Alessandro Andriani, MD, Daniele Caracciolo, MD, Anna Guidetti, MD, Fiorella Ilariucci, MD, Stefano Luminari, MD, Antonino Mulè, MD, Edi Viale, MD, Paolo Giorgio Arcidiacono, MD, Maurilio Ponzoni, MD, Andrés J.M. Ferreri, MD

Blood (2011) 118 (21): 958.

https://doi.org/10.1182/blood.V118.21.958.958

Published: 2011

Journal Articles

Dexamethasone, Cytarabine and Cisplatin or Oxaliplatin Schedule (DHAP or Ox-DHA) Is Effective and Widely Applicable in Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia.

Marco Ruella, MD, Irene Ricca, MD, Angela Gueli, MD, Daniela Gottardi, MD, Daniele Caracciolo, MD, Luciana Bergui, MD, Paolo Gavarotti, MD, Alberto De Crescenzo, MD, Lucia Farina, Paolo Corradini, MD, Corrado Tarella, MD

Blood (2009) 114 (22): 3434.

https://doi.org/10.1182/blood.V114.22.3434.3434

Published: 2009

Journal Articles

Male Gender, Quality of Grafted Cells, Advanced Age, Rituximab and Radiotherapy Are the Main Factors That Variously Influence the Occurrence of Secondary Malignancies Following High-Dose Therapy and Autograft: A GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Survey in 1,347 Lymphoma Patients.

Blood (2009) 114 (22): 519.

https://doi.org/10.1182/blood.V114.22.519.519

Published: 2009

Journal Articles

Non-Hodgkin’s Lymphoma Refractory to First Line Therapy: Incidence, Associated Clinical and Histological Factors, and Outcome among 503 Newly Diagnosed Patients.

Angela Gueli, MD, Daniele Caracciolo, MD, Manuela Zanni, MD, Luciana Bergui, MD, Paolo Gavarotti, MD, Marco Ladetto, MD, Andrea Filippi, MD, Roberto Passera, PhD, Mario Boccadoro, MD, Corrado Tarella, MD

Blood (2007) 110 (11): 1373.

https://doi.org/10.1182/blood.V110.11.1373.1373

Published: 2007

Journal Articles

Telomere Length of Hematopoietic Cells Following Autologous and Allogeneic Stem Cell Transplant (SCT) Reflects That of Grafted Cells: Can the Transplant of Younger Stem Cells Be Exploited To Rejuvenate Hematopoiesis?.

Alberto Rocci, MD, Marco Ruella, MD, Irene Ricca, MD, Cristiana Carniti, PhD, Manuela Zanni, MD, Chiara Lobetti Bodoni, MD, Marco Ladetto, MD, Daniele Caracciolo, MD, Mario Boccadoro, MD, Paolo Corradini, MD, Corrado Tarella, MD

Blood (2007) 110 (11): 3025.

https://doi.org/10.1182/blood.V110.11.3025.3025

Published: 2007

Journal Articles

Patients with aaIPI 2-3 Diffuse Large B-Cell Lymphoma Achieve 75% Long-Term Survival Following First-Line Rituximab-Supplemented High-Dose Sequential Chemotherapy and Autograft: Final Results of the Prospective Phase II GITIL ( Gruppo Italiano Terapie Innovative nei Linfomi ) Trial.

Corrado Tarella, MD, Manuela Zanni, MD, Massimo Di Nicola, MD, Caterina Patti, MD, Claudia Castellino, MD, Roberto Crocchiolo, MD, Valerio Zoli, MD, Daniele Caracciolo, MD, Michele Magni, MD, Mario Boccadoro, MD, Fabio Ciceri, MD, Paolo Corradini, MD, Andrea Gallamini, MD, Ignazio Majolino, MD, Salvo Mirto, MD, Alessandro M. Gianni, MD

Blood (2007) 110 (11): 1889.

https://doi.org/10.1182/blood.V110.11.1889.1889

Published: 2007

NARROW

An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma

A Novel Bispecific T Cell Engager (UMG2-BTCE) Targeting CD1a-CD3ε Is Effective Against Cortical-Derived Acute Lymphoblastic Leukemia

Global Rnaseq/Proteomic-Phoshoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM

PARP1-Mediated Alt-NHEJ Repair Is a Therapeutic Target in Multiple Myeloma

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92

Th17 Cells Targeting By MiR-21 Inhibitor Impairs Multiple Myeloma Related Bone Disease

Life Expectancy in Follicular Lymphoma Is Mainly Determined By Response to First LINE Treatment: A LONG-TERM Survey on 597 Patients

Targeting Aberrant Non-Homologous End Joining in Multiple Myeloma: Role of the Classical and Alternative Pathways in Genomic Instability

Relapsed Or Refractory Aggressive Non Hodgkin B-Cell Lymphomas Treated With Lenalidomide With/Without Rituximab Or Steroids: A Single Center Restrospective Study

In Vitro and Vivo Activity Against Multiple Myeloma Cells Of a Novel Locked Nucleic Acid (LNA)-Mir-221 Inhibitor

The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab

Primary Refractory Disease in Non-Hodgkin's Lymphoma: A Retrospective Study On 3,952 Newly Diagnosed Patients Undergoing First-Line Chemotherapy

Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial

Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results,

Final Results of a Multicenter Phase II Trial Assessing the Activity and Efficacy of Helicobacter Pylori -Eradicating Antibiotic Therapy As Exclusive Treatment for Patients with Stage I-II1 Diffuse Large B-Cell Lymphoma of the Stomach (the HGL-1 Trial)

Dexamethasone, Cytarabine and Cisplatin or Oxaliplatin Schedule (DHAP or Ox-DHA) Is Effective and Widely Applicable in Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia.

Non-Hodgkin’s Lymphoma Refractory to First Line Therapy: Incidence, Associated Clinical and Histological Factors, and Outcome among 503 Newly Diagnosed Patients.

Telomere Length of Hematopoietic Cells Following Autologous and Allogeneic Stem Cell Transplant (SCT) Reflects That of Grafted Cells: Can the Transplant of Younger Stem Cells Be Exploited To Rejuvenate Hematopoiesis?.

Patients with aaIPI 2-3 Diffuse Large B-Cell Lymphoma Achieve 75% Long-Term Survival Following First-Line Rituximab-Supplemented High-Dose Sequential Chemotherapy and Autograft: Final Results of the Prospective Phase II GITIL ( Gruppo Italiano Terapie Innovative nei Linfomi ) Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only